https://www.myeloma.org/videos/top-myeloma-research-presented-ash-2022
Both Linda and Nick are attending this year's ASH annual meeting. Of the more than 3,000 abstracts presented at the 2022 ASH meeting, 1,041 were related to multiple myeloma. Some of the topics of utmost interest to the myeloma community include the following: Bispecific Antibodies. CAR T Frontline.

https://www.myeloma.org/imf-ash-2022
Top Myeloma Research Presented at ASH 2022 Of the more than 3,000 abstracts presented at the 2022 ASH meeting, 1,041 were related to multiple myeloma. In this webinar, IMF Chairman of the Board Dr. Brian G.M. Durie highlights the top myeloma abstracts presented during the annual conference

https://www.myeloma.org/blog/top-myeloma-abstracts-ASH-2022
Top Abstracts of Interest at the ASH 2022 Myeloma Sessions. Post date. December 14, 2022. Week in Review. Each year, myeloma sessions at the American Society of Hematology (ASH) Summit have different patterns of interest and importance. This year, bispecific antibodies became the area of great excitement, with results from many trials reported.

https://www.youtube.com/watch?v=3HeipgL5Zy0
Dr. Brian G.M. Durie discusses important takeaways relating to multiple myeloma from the annual American Society of Hematology (ASH) conference.In this webin

https://us.engagingnetworks.app/page/email/message/view?templateId=216095
In this webinar, "Top Myeloma Research Presented at ASH 2022: What Patients and Care Partners Need to Know," IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G. M. Durie summarizes key takeaways that impact the myeloma community from the 2022 American Society of Hematology (ASH) Annual Meeting.

https://ashpublications.org/hematology/article/2022/1/356/493539/The-burden-of-myeloma-novel-approaches-to-disease
Multidrug combinations of novel agents can achieve conventional CR (defined as negative IFE on the serum and urine, the disappearance of any soft tissue plasmacytomas, and less than 5% plasma cells in BM aspirates) in more than two-thirds of patients. 1-3 Trial and "real-world" data consistently demonstrate that both transplant eligible and ineligible patients achieving CR after first-line

https://us.engagingnetworks.app/page/email/message/view?templateId=209869
The "Top Myeloma Research Presented at ASH 2022: What Patients and Care Partners Need to Know" webinar will take place on Tuesday, December 20, 2022, at 4:00 p.m. PST | 5:00 p.m. MST | 6:00 p.m. CST | 7:00 p.m. EST. In this webinar, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G. M. Durie will summarize key takeaways

https://www.myelomacenter.org/news/ash-2022-%E2%80%93-myeloma-research-updates
The meeting featured exciting new research from physicians and scientists, including our team members who were involved with important research for myeloma and related plasma cell disorders. The Weill Cornell Medicine (WCM) Myeloma Center was involved with numerous abstracts presented at ASH 2022.

https://www.targetedonc.com/view/kumar-reviews-key-trials-on-multiple-myeloma-presented-at-ash-2022
Kumar Reviews Key Trials on Multiple Myeloma Presented at ASH 2022. February 24, 2023. Jonah Feldman. Article. In an interview with Targeted Oncology, Shaji K. Kumar, MD, discussed the presentations from ASH 2022 that stood out as most important to the multiple myeloma landscape. Shaji K. Kumar, MD.

https://us.engagingnetworks.app/page/email/message/view?templateId=211738
The "Top Myeloma Research Presented at ASH 2022: What Patients and Care Partners Need to Know" webinar will take place on Tuesday, December 20, 2022, at 4:00 p.m. PST | 5:00 p.m. MST | 6:00 p.m. CST | 7:00 p.m. EST. In this webinar, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G. M. Durie will summarize key takeaways

https://healthtree.org/myeloma/community/articles/ASH-2022-a-sampling-of-the-research
Continue to watch HealthTree as we share additional updates on the breaking myeloma research coming from ASH 2022. Vicki is a volunteer HealthTree Coach. She actively educates herself on myeloma, the latest research and resources available and shares what she learns with those she coaches. find or become a Healthtree coach

https://ash2022blogs.myeloma.org/significance-of-the-last-decade/
All of these bring great promise and hope to myeloma patients. Please join me as I participate in Dr. Durie's Top Myeloma Research Presented at ASH 2022 on Tuesday, December 20 at 7:00 p.m. ET and I wish you all a healthy New Year and promise that 2023 will bring even more advancements toward a cure for multiple myeloma!

https://www.myeloma.org/blog/key-takeaways-ash-2022
Key Takeaways from the 2022 American Society of Hematology (ASH) Conference What myeloma patients and family and friends need to know I am pleased to share with readers of Myeloma Today an overview of the top abstracts of interest presented during myeloma sessions at the 64th Annual Meeting & Exposition of the American Society of Hematology (ASH) in December 2022. Impressively, more than 1,000

https://www.myeloma.org/videos/key-multiple-myeloma-abstracts-presented-ash-2022
IMF Chief Medical Officer Dr. Joseph Mikhael discusses the top Multiple Myeloma Abstracts presented at ASH 2022. Read more. Read more. Previous Post. Next Post. $25. $50. $100. $150.

https://healthtree.org/myeloma/community/articles/ASH-2022-from-incurable-to-cured
At the ASH meeting, Dr. Luciano Costa presented Abstract 3237 which provides extended follow-up from the Master Trial. Let me get right to the authors' bold conclusion for newly diagnosed multiple myeloma (NDMM) patients, "For the majority of patients with NDMM, quadruplet therapy, ASCT and MRD response-adjusted treatment modulation

https://multiplemyelomahub.com/medical-information/after-ash-2022-are-we-closer-to-using-mrd-guided-treatment-decisions-in-mm
Derman BA, Major A, Major S, et al.. Prospective trial using multimodal measurable residual disease negativity to guide discontinuation of maintenance therapy in multiple myeloma (MRD2STOP). Oral abstract #870. Presented at: 64th American Society of Hematology Annual Meeting and Exposition; Dec 12, 2022; New Orleans, US.

https://ashpublications.org/hematology/article/2022/1/180/493528/Cellular-therapy-for-multiple-myeloma-what-s-now
The incidence of CRS was 95%, mostly grade 1 to 2, with a median time to onset of 7 days (range, 1-12). Neurological events were reported in 20 patients. Among these, 16 presented immune-effector cell-associated neurotoxicity syndrome (ICANS), and 12 patients presented with other neurotoxicities.

https://finance.yahoo.com/news/eha-2024-monoclonal-antibodies-continue-215426629.html
Many significant Phase I-III studies targeting haematological malignancies, such as multiple myeloma (MM), were presented at the European Hematology Association Hybrid Congress 2024 (EHA 2024

https://health.usnews.com/doctors/matthew-mccarty-251945
Dr. Matthew J. McCarty is a Oncologist in Maryville, TN. Find Dr. McCarty's phone number, address, insurance information, hospital affiliations and more.

http://tnwrrc.tennessee.edu/watersheds/waterfaculty.html
TN Water Resources Research Center Institute for a Secure and Sustainable Environment. 311 Conference Center Building, Knoxville, Tennessee 37996-4134 Phone: 865-974-2151 Email: tnwrrc@utk.edu. The University of Tennessee. The University of Tennessee, Knoxville Knoxville, Tennessee 37996

https://www.southernorthocare.com/copy-of-middlesboro
View Larger Map Southern Orthocare. 2022 Chilhowee Medical Park. Maryville, TN 37804-5285. Phone: 865-855-9701. Fax: 865-855-9702

https://www.myeloma.org/videos/imwg-conference-series-ash-2022
ASH 2022: Making Sense of Treatment In the IMWG Conference Series, "Making Sense of Treatment," leading myeloma experts discuss the latest myeloma news from the 64th American Society of Hematology Annual Meeting in December 2022 Moderated by IMF Chairman of the Board Dr. Brian G.M. Durie, panelists includes María V. Mateos (University of Salamanca—Salamanca, Spain) and Dr. Thomas Martin

https://etaddiction.com/contact-us/
Contact Us. 9301 Parkwest Blvd. Suite B-4 Knoxville, TN 37923. Phone: 865-268-4360. Email: etaddiction@gmail.com. We are conveniently located at 2022 Chilhowee Medical Park, Maryville , TN and 101 Sherlake Dr Suite 106 in Knoxville. Our hours of operation are by appointment only. We currently accept Amerigroup Tncare insurance and are a

https://www.myeloma.org/videos/multiple-myeloma-abstracts-dealing-health-disparities-presented-ash-2022
Multiple Myeloma Abstracts Dealing with Health Disparities Presented at ASH 2022. ASH 2022. February 01, 2023. ASH. IMF Chief Medical Officer Dr. Joseph Mikhael discussed the latest research on these healthcare disparities as they were reported on during the 2022 American Society of Hematology annual conference. For more information about the